A practical reference on REV-ERB agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-26. Anything still debated is marked as such rather than presented as settled.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
== Aftermath == An internal review estimated that the pursuit had cost the public £3 million and that vital scientific information had been missed. The criminal psychologist involved with the investigation was charged with professional misconduct by the British Psychological Society, but in 2002, in lieu of any substantial hearings, further action was dismissed due to the delay in bringing proceedings. André Hanscombe moved with his and Nickell's child to France. He was strongly critical of some of the reporters who tracked him and his son down to his "sanctuary" in the French countryside. In 1996 Hanscombe wrote a book titled The Last Thursday in July about his life with Nickell, coping with the homicide, how "media intrusion" drove him to move abroad, and life with their son afterwards. In 2017 Alex Hanscombe wrote a memoir, Letting Go: A True Story Of Murder, Loss & Survival, telling the story of his mother's murder and how he coped with his grief and trauma.
=== Bioanalysis === Biomolecules in samples such as galactose can be quantified using oxygen detection method, since one equivalent consumption of oxygen corresponds to one equivalent primary hydroxyl group oxidized. The formation of hydrogen peroxide during substrate oxidation can also be used for colorimetric detection of galactose using dyes that are oxidized by hydrogen peroxide. Because carbohydrates can normally have primary hydroxyl groups, galactose oxidase can be used to modify cell surface glycoproteins to achieve cell labelling.
=== Responses to criticism === Marxist–Leninists respond that there was generally no unemployment in communist states and all citizens were guaranteed housing, schooling, healthcare and public transport at little or no cost. In his critical analysis of communist states, Ellman stated that they compared favourably with Western states in some health indicators such as infant mortality and life expectancy. Philipp Ther wrote that there was a rise in living standards throughout Eastern Bloc countries as the result of modernisation programs under Marxist–Leninist governments. Sen found that several communist states made significant gains in life expectancy and commented "one thought that is bound to occur is that communism is good for poverty removal." Olivia Ball and Paul Gready reported that communist states pressed Western governments to include economic rights in the Universal Declaration of Human Rights. Others such as Parenti stated that communist states experienced greater economic development than they would have otherwise, or that their leaders were forced to take harsh measures to defend their countries against the Western Bloc during the Cold War.
=== Embryogenesis === In male mammals, AMH prevents the development of the Müllerian ducts into the uterus and other Müllerian structures. The effect is ipsilateral, that is each testis suppresses Müllerian development only on its own side. If no hormone is produced from the gonads, the Müllerian will develop thanks to the presence of Wnt4, while the Wolffian ducts, which are responsible for male reproductive parts, will die due to the presence of COUP-TFII. Amounts of AMH that are measurable in the blood vary by age and sex. AMH works by interacting with specific receptors on the surfaces of the cells of target tissues (anti-Müllerian hormone receptors). The best-known and most specific effect, mediated through the AMH type II receptors, includes programmed cell death (apoptosis) of the target tissue (the fetal Müllerian ducts). Phylogenetically, the amh gene first appears among cartilaginous fishes in line with the appearance of paired Müllerian ducts. In teleost fishes, there is no Müllerian duct, as male and female both develop gonoducts as a posterior extension of the gonads. Despite this, amh is expressed. During embryo development, the undifferentiated gonads express amh expression at low and equal levels for both sexes. Later, in males, amh expression increases and remains high during and after puberty in adults. In the female chicken embryo, the right duct and the right gonad regresses, both mediated by AMH, but the left duct remains, likely protected by estrogen.
Sources: en.wikipedia.org
=== Errors in translation === Even though the ribosomes are usually considered accurate and processive machines, the translation process is subject to errors that can lead either to the synthesis of erroneous proteins or to the premature abandonment of translation, either because a TRNA couples to a wrong codon or because a TRNA is coupled to the wrong amino acid. The rate of error in synthesizing proteins has been estimated to be between 1 in 105 and 1 in 103 misincorporated amino acids, depending on the experimental conditions. The rate of premature translation abandonment, instead, has been estimated to be of the order of magnitude of 10−4 events per translated codon.
Polylactic acid (PLA) is a synthetic biodegradable polymer widely used as a dermal filler for soft tissue augmentation, classified into two stereoisomeric forms: poly(L-lactic acid) (PLLA) and poly(D,L-lactic acid) (PDLLA), both of which are widely used as dermal fillers, though variations in their physicochemical properties may lead to differences in handling characteristics and clinical performance. Unlike hyaluronic acid fillers that provide immediate volume, PLLA particles remaining after carrier absorption are degraded into lactic acid, which enhances collagen synthesis by fibroblasts, while immune cells recognize PLLA as a foreign body, initiating macrophage recruitment that induces fibroblast recruitment and fibrotic tissue formation.
== History == GABA is the principal inhibitory neurotransmitter in mammalian brains. By the early 1970s, it was appreciated that there are two main classes of GABA receptors, GABAA and GABAB and also that baclofen was an agonist of GABAB receptors. Gabapentin was designed, synthesized, and tested in mice by researchers at the pharmaceutical company Goedecke AG in Freiburg, Germany (a subsidiary of Parke-Davis). It was meant to be a structural analog of the neurotransmitter GABA that could more easily cross the blood–brain barrier. It was first synthesized in 1974/75 and described in 1975 by Satzinger and Hartenstein. The first pharmacology findings published were sedating properties and prevention of seizures in mice evoked by the GABA antagonist, thiosemicarbazide. Shortly after, gabapentin was shown in vitro to reduce the release of the neurotransmitter dopamine from slices of rat caudate nucleus (striatum). This study provided evidence that the action of gabapentin, unlike baclofen, did not arise from the GABAB receptor. Initial clinical trials using small numbers of subjects were for treatment of spasticity and migraine but neither study had statistical power to allow conclusions. In 1987, the first positive results with gabapentin were obtained in a clinical trial using three dose groups versus pre-treatment seizure frequency for 75 days, as add-on treatment in patients who still had seizures despite taking other medications. Under the brand name Neurontin, it was first approved in the United Kingdom in May 1993, for the treatment of refractory epilepsy.
Sources: en.wikipedia.org
== After Liberation == Smolková-Keulemansová suffered from dysentery, jaundice, typhus and tuberculosis after liberation. She could not give an address to anyone she knew in Prague, so the International Red Cross did not allow her to return to her country of origin. To receive medical treatment, she was selected to go to Sweden for a six-month recovery stay with 6,000 other prisoners.
Actin, cytoplasmic 2, or gamma-actin is a protein that in humans is encoded by the ACTG1 gene. Gamma-actin is widely expressed in cellular cytoskeletons of many tissues; in adult striated muscle cells, gamma-actin is localized to Z-discs and costamere structures, which are responsible for force transduction and transmission in muscle cells. Mutations in ACTG1 have been associated with nonsyndromic hearing loss and Baraitser-Winter syndrome, as well as susceptibility of adolescent patients to vincristine toxicity.
== See also == Nanomedicine, the general field Micelle, lipid cored Liposome, lipid bilayer shell, an earlier form with some limitations Lipoplex, a complex of plasmid or linear DNA and lipids Targeted drug delivery mRNA-1273, from Moderna, uses LNPs BNT162b2, from BioNTech/Pfizer, uses LNPs
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.